Plain-English translation of NCT07092007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new medication called NWRD09, which is given as injections into your muscle, to see if it's safe and works for women with HPV-related cervical cell changes or cervical cancer. The trial has two main groups: one for women with early precancerous changes and one for women with advanced cervical cancer. Researchers will carefully increase the dose in small groups of patients to find the right amount that works best.
HPV-16 is a virus that can cause serious cervical cell changes and cancer, and current treatments don't work for everyone or may cause severe side effects. This trial is exploring whether this new medication could offer another option for women whose disease has come back, progressed despite treatment, or who couldn't tolerate standard therapies.
You will receive NWRD09 as muscle injections in gradually increasing doses over time. For precancerous changes, you'll have safety check-ups for 2 weeks after your last injection and then a detailed examination with tissue sampling at 24 weeks. For advanced cancer, you'll have regular imaging scans every 6 weeks to check how your tumors are responding. The entire trial will include a small group of patients (9–18 total) to carefully monitor safety as doses increase.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Sponsor
Newish Technology (Beijing) Co., Ltd.
Enrollment target
~18 participants
Started
June 2024
Primary completion
December 2025
Age range
18 Years – 60 Years
Sex
Female only
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guodong Sun, Master
Newish Technology (Beijing) Co., Ltd.